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Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis that affects many psoriasis 
patients and can often have a debilitating disease progression. Golimumab is a new tumor necrosis 
factor (TNF) antagonist recently approved by the FDA for controlling signs and symptoms of 
psoriatic arthritis. In a Phase III clinical trial in patients with PsA, patients receiving golimumab 
showed significant improvement in the signs and symptoms of disease. It was usually well toler-
ated, but adverse events generally occurred more in patients receiving golimumab compared to 
placebo. Golimumab has also recently shown efficacy in slowing structural damage in PsA. This 
new biologic therapy provides physicians with another option in the treatment of this inflamma-
tory arthritis while offering patients certain advantages over other TNF antagonists.
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Introduction
Psoriatic arthritis is a seronegative inflammatory arthritis that affects approximately 
0.25% of the general population in the United States and approximately 14% of 
  psoriasis patients according to one recent study, though reported numbers have reached 
over 40%.1–3 Psoriatic arthritis can often present a diagnostic challenge due to a wide 
range of clinical presentations, degrees of severity, and may be difficult to distinguish 
from other inflammatory arthritides. The disease progression of PsA is variable and 
patients often present only with skin involvement for years before developing any joint 
symptoms. The symptoms described by psoriatic arthritics may present as less severe 
relative to other inflammatory arthritis such as rheumatoid arthritis (RA), and may be 
deemed a milder form despite underlying structural damage.3 A complicated clinical 
picture and a paucity of symptoms may cause a delay in diagnosis and treatment which 
could then lead to a quiet progression of the structural damage.
Once diagnosed, appropriate treatment of PsA, based the severity of disease, 
should be initiated to improve the signs and symptoms and minimize the negative 
disease impact on patients’ lives. For mild disease, this typically involves the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and/or corticosteroid 
injections. For moderate to severe disease, more aggressive treatment is necessary in 
order to inhibit progression of structural damage. Disease-modifying antirheumatic 
drugs (DMARDs) are available, but their efficacy in PsA when used alone has not been 
well established. TNF blockade with or without methotrexate has been demonstrated 
to control signs and symptoms, inhibit X-ray progression and improve quality of life 
in patients with PsA.4–6
Melissa A Michelon1
Alice B Gottlieb1,2
1Tufts University School of Medicine, 
2Department of Dermatology, Tufts 
Medical Center, Boston, MA, USAClinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
80
Michelon and Gottlieb
There are a number of options for biologic treatments, 
particularly the TNF antagonists. Most show similar efficacy 
and side effect profiles. Golimumab, one of the newest TNF 
blockers, was recently shown to be efficacious in improving 
not only the signs and symptoms of PsA, but also in treat-
ing the structural damage caused by the disease making it a 
reasonable option in treating moderate to severe PsA.
Mode of action
Golimumab is one of the newer TNF antagonists to become 
available and is currently indicated for controlling the signs 
and symptoms of active PsA in adult patients. Manufactured 
by Centocor Ortho Biotech, Inc (Horsham, PA, USA) under 
the trade name Simponi, golimumab is a fully human anti-
TNF IgG monoclonal antibody with affinity for both soluble 
and transmembrane TNF.7 It targets and neutralizes a key 
contributing factor in the inflammatory process as well as the 
pathophysiology of chronic inflammatory diseases, including 
RA, PsA, and ankylosing spondylitis (AS).8
Pharmacokinetics
Serum concentrations of golimumab were generally dose-
proportional in Phase III clinical trials,9,10 though Kay et al 
also reported a large variation between patients.11 Steady-state 
concentrations of golimumab were achieved by Week 12 in 
these trials.9–11
Xu et al determined population pharmacokinetic 
parameters of golimumab based on data collected in the 
GO-REVEAL study of patients with PsA.9,12 Analysis 
of serum concentrations showed an apparent clearance of 
1.38 ± 0.04 L/d and an apparent volume of distribution of 
24.9 ± 1.04 L for patients weighing a standard 70 kg.12 The 
authors found that body weight was a significant covariate for 
both the apparent clearance and apparent volume of distribu-
tion. Patients receiving the 50 mg dose of golimumab and 
with a body weight greater than 100 kg showed less improve-
ment based on American College of Rheumatology (ACR) 
criteria than those patients weighing less than 100 kg receiv-
ing the same dose. This difference in response rates based 
on body weight was not as evident in the patients receiving 
the 100 mg dose of golimumab, and the authors suggested 
that a dose adjustment may be necessary in patients weigh-
ing over 100 kg.12 Other significant covariates found for the 
apparent clearance included antibodies to golimumab status, 
smoking status, and baseline C-reactive protein level. The 
use of concomitant medications, including NSAIDs, corti-
costeroids, and methotrexate, was also analyzed for potential 
effects. In the group receiving the 50 mg golimumab dose, 
there appeared to be a reduction in clearance of golimumab 
with concomitant use of methotrexate, but this effect was not 
seen in the group receiving the 100 mg dose of golimumab 
and overall was not significant. The authors also determined 
a half-life for golimumab of 12.5 days.12
Efficacy
In the Phase III clinical trial of golimumab in patients with 
active PsA, significant improvement in the signs and symp-
toms of the disease was shown following treatment with 
golimumab at doses of 50 mg and 100 mg every 4 weeks.9 
Kavanaugh et al also found that 51% of patients treated with 
50 mg golimumab and 45% of patients treated with 100 mg of 
golimumab achieved an American College of Rheumatology 
20% improvement criteria (ACR20) response at week 14, the 
study’s primary endpoint, compared to only 9% in patients 
receiving placebo (P , 0.001 for both comparisons). This 
efficacy of golimumab was maintained at week 24 of the trial 
where 52% of patients in the 50 mg golimumab and 61% in 
the 100 mg golimumab groups achieved an ACR20 response 
compared to only 12% in the placebo group (P , 0.001 for 
both comparisons).9 This response is comparable to that 
observed with other TNF antagonists (see Table 1).
Approximately half of the patients in this trial were 
also taking stable doses of concomitant methotrexate. The 
proportion of patients on methotrexate and their mean dos-
ages were similar in all treatment groups and the ACR20 
response at week 14 was observed regardless of methotrex-
ate use.9
Patients in this same study with at least 3% body surface 
area (BSA) affected by psoriasis were also evaluated for 
changes in the Psoriasis Area and Severity Index (PASI) 
score. It was found that 40% of these patients in the 50 mg 
golimumab group and 58% in the 100 mg golimumab group 
achieved a 75% improvement in their PASI score (PASI75) 
at week 14 compared to only 3% of patients receiving 
placebo (P , 0.001 for both comparisons). At week 24, 
56% of patients in the 50 mg golimumab group and 66% 
Table 1 Efficacy comparison of golimumab (50 mg once monthly) 
and other TNF antagonists4–6,9
TNF antagonist ACR20 response at 
week 12 or 14a
PASI75 at 
week 24
etanercept 59% 23%
Adalimumab 58% 59%
Infliximab 58% 60%
Golimumab 51% 56%
aACR20 response observed at week 12 for etanercept and adalimumab, at week 14 
for infliximab and golimumab.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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in the 100 mg group achieved a PASI75 compared to 1% 
in the   placebo group (P , 0.001 for both comparisons) 
(Table 1).
Changes in nail involvement were also assessed using 
the Nail Psoriasis Severity Index (NAPSI) and Physician’s 
Global Assessment (PGA) of psoriatic nail disease. Patients 
treated with golimumab showed significant improvement 
in nail involvement compared to placebo at week 14 and 
at week 24.9
The proportion of patients with enthesitis in the 50 mg 
and 100 mg golimumab groups was 49% and 50%, respec-
tively, compared to 69% in the placebo group at week 24 
(P = 0.002 and P = 0.003, respective comparisons). Sig-
nificant improvement in the PsA-modified Maastricht 
Ankylosing Spondylitis Enthesitis Score (MASES) was 
also observed. A 60% median change was observed in those 
receiving 50 mg golimumab and 67% in those receiving 
100 mg golimumab compared to only a 12% median score 
change in those receiving placebo (P , 0.001 for both). There 
was no significant difference observed in the proportion of 
patients with dactylitis through week 24, though the severity 
of dactylitis had significantly improved in patients treated 
with 100 mg of golimumab relative to placebo.9
Kavanaugh et al also showed that golimumab was 
  efficacious in improving physical function and quality of 
life. They observed that patients treated with golimumab 
had significantly improved Health Assessment Ques-
tionnaire (HAQ) and Short-Form 36 (SF-36) scores at 
week 14 compared to placebo.9
Long-term efficacy of golimumab has been observed; 
with continued response rates through 2 years of treatment.13 
The proportion of patients who remained on the 50 mg dose 
of golimumab achieving an ACR20 response at weeks 52 and 
104 were 78% and 91%, respectively. Patients who remained 
on the 100 mg dose also showed continued response at week 
52 with 81% achieving an ACR20, though the proportion of 
patients with that response decreased to 73% at week 104. In 
the 50 mg group, 62% and 69% of patients achieved a PASI75 
at weeks 52 and 104, respectively. In the group treated with 
100 mg of golimumab, 70% and 76% of patients achieved a 
PASI75 at weeks 52 and 104, respectively. Improvement in 
HAQ scores was also maintained for both groups through 
week 104.13
Radiographic changes
Additionally, golimumab has been shown to slow structural 
joint damage, specifically articular erosions and joint space 
narrowing, which has been observed radiographically. 
Kavanaugh et al recently reported that PsA patients   receiving 
golimumab showed significantly less progression of joint 
space disease at week 52 of treatment compared to those 
receiving placebo.14
Safety and tolerability
Golimumab was usually well tolerated in Phase III trials, 
but adverse events generally occurred more in patients 
receiving golimumab compared to placebo. Kavanaugh et al 
reported adverse events in 65% of all golimumab-treated 
patients compared to 59% of those receiving placebo, and 
serious adverse events in 2% and 6% of patients, respec-
tively.9 Similarly, Inman et al reported 85.6% of patients 
treated with golimumab and 76.6% of patients receiving 
placebo reported at least one adverse event, whereas 5.4% 
of the golimumab-treated patients reported at least 1 seri-
ous adverse event compared to 6.5% of patients receiving 
placebo.10
The side effect profile of golimumab is similar to that of 
other TNF antagonists.4–6
Common adverse reactions
Injection site reactions were among the common adverse reac-
tions reported in Phase III clinical trials of golimumab.9–11,15–17 One 
trial reported injection site reactions at a rate of 8.7% in the 
50 mg golimumab group and 6.4% in the 100 mg group com-
pared to 2.6% in the placebo group.10 Kavanaugh et al reported 
that injection site reactions in the combined golimumab group 
(3%) were comparable to the placebo group (3%).9 The most 
common reaction was erythema, which was generally mild 
and did not lead to discontinuation of treatment.9,11,15–17 No 
anaphylactic reactions have been reported for golimumab 
in clinical trials. Other common adverse reactions in these 
trials included upper respiratory infections, nasopharyngitis, 
and headache.9,11,15,16 Similar common adverse events were 
observed in clinical trials of other TNF antagonists.4–6
Infections
In Phase III clinical trials, more subjects receiving 
  golimumab developed any type of infection during the 
study periods compared to those receiving placebo9–11 or 
methotrexate alone.16 Though uncommon, serious infec-
tions, including sepsis and pneumonia, have been reported 
in patients taking golimumab similar to those taking other 
TNF antagonists. Kay et al reported 3 patients treated with 
golimumab who developed pneumonia, including 1 patient 
who also developed septic shock, and 1 patient in the placebo 
group developed a lower respiratory infection.11 Because Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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  infections can be serious, even fatal,16 golimumab should not 
be   prescribed to patients with evidence of an active infection 
or are immunocompromised.
TNF is thought to play an important role in host defense 
against infection, particularly against intracellular bacteria,8 
inferring a degree of susceptibility to these types of infec-
tions with the use of TNF antagonists. In Phase III trials of 
golimumab, anti-tuberculosis treatment was initiated prior to 
entering the study in patients who showed evidence of latent 
tuberculosis infection.9,10,16,17 One case of tuberculosis of the 
spine was reported in a patient receiving golimumab during 
these trials.17 The diagnosis had been made only after the 
patient’s treatment with golimumab began, was based on the 
observation of caseating granulomas in a surgical specimen, 
and the diagnosis was not confirmed by any other method. 
No other cases of active or reactivation tuberculosis were 
reported in clinical trials. It is recommended that all patients 
be screened for evidence of latent infection and treated appro-
priately prior to initiation of treatment with golimumab.
Abnormal laboratory values
Elevations in liver enzymes were reported in trials of goli-
mumab. More patients receiving golimumab had increased 
liver transaminases compared to placebo. Kavanaugh et al 
reported 24% of patients in the 50 mg golimumab group, 
35% in the 100 mg golimumab group, and 18% in the 
placebo group had elevations in alanine aminotransferase 
(ALT) levels. Aspartate aminotransaminase (AST) was also 
elevated in 18%, 13%, and 10% of patients, respectively.9 
Patients were generally asymptomatic and most of these 
elevations were not serious.9,10 Many of the patients with 
increased AST and ALT levels were concurrently receiving 
other medications such as isoniazid for treatment of latent 
tuberculosis9,10 or methotrexate.10 However, Emery et al did 
not find an increased risk of serious AST or ALT elevations 
with concomitant use of golimumab and isoniazid.17
Two cases of anemia were reported in a Phase III clini-
cal trial in patients receiving 100 mg of golimumab plus 
placebo.17
Malignancy
Patients treated with any of TNF antagonists, including 
golimumab, may be at higher risk for developing certain 
malignancies, including lymphoma, than the general popu-
lation. It is not clear, however, if the presence of a chronic 
inflammatory disease, like rheumatoid arthritis, itself may 
predispose patients to developing lymphoma.18 Only solid 
malignancies were reported in one Phase III clinical trial, 
two cases of basal cell carcinoma and one case of prostate 
cancer in the group receiving a higher dose of golimumab 
(100 mg monthly) compared to no reports of malignancy 
in the lower golimumab dose (50 mg monthly) or placebo 
groups through week 24 of the study.9 Smolen et al reported 
a case of squamous cell carcinoma of the skin in a patient 
receiving 50 mg golimumab, lymphoma in a patient receiv-
ing 100 mg golimumab, and pancreatic cancer in a patient 
receiving placebo.15 Emery et al reported breast cancer and 
squamous cell carcinoma of the lip in patients receiving 
methotrexate plus placebo, another case of breast cancer 
in a patient receiving 50 mg golimumab plus methotrexate, 
and Hodgkin’s lymphoma in a patient receiving 100 mg 
golimumab plus methotrexate.17 Keystone et al also reported 
four malignancies, two cases of non-melanoma skin cancer 
in patients receiving 100 mg golimumab alone and one case 
of breast cancer in a patient receiving 100 mg golimumab 
and methotrexate compared to 1 case of basal cell cancer in 
a patient taking methotrexate alone.16
Congestive heart failure
TNF antagonists, including golimumab, can potentially 
exacerbate CHF.19 In a Phase III clinical trial in patients 
with rheumatoid arthritis despite methotrexate treatment one 
patient reported congestive heart failure.11 New onset CHF 
has also been reported with other TNF antagonists. Care 
should be taken when prescribing golimumab in patients 
with CHF and they should be monitored routinely for signs 
and symptoms of deterioration of their condition or newly 
developing CHF.
Autoimmunity
The development of autoantibodies, particularly antinuclear 
and anti-dsDNA antibodies, is associated with the use of TNF 
antagonists.20 Inman et al reported 10.1% of patients receiv-
ing 50 mg golimumab, 14.8% of those receiving 100 mg 
golimumab, and 12.9% receiving placebo were newly posi-
tive for antinuclear antibodies, but only one of these patients 
developed anti-dsDNA antibodies.10 In another clinical trial, 
the rate of antinuclear antibodies in the golimumab plus 
methotrexate treated groups was 12.2% (combined) and was 
comparable to placebo plus methotrexate (14.9%). The rate 
of antinuclear antibodies was found to be higher in the goli-
mumab alone group (29.3%).16 One case of systemic lupus 
erythematosus (SLE) was reported in Phase III clinical trials. 
The patient had tested positive for antinuclear antibodies prior 
to treatment initiation and developed SLE within days after 
receiving their first dose of golimumab.15 Currently, there Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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are no recommendations for monitoring of autoantibodies in 
patients taking TNF antagonists. Antibodies to golimumab 
itself were found in 2.1% to 6.3% of golimumab-treated 
patients9,16,17 in Phase III clinical trials, though none of the 
patients receiving methotrexate at baseline developed anti-
bodies to the drug.9
Warnings
Potential class effects
Other TNF antagonists have been associated with additional 
adverse events that were not reported for golimumab in 
the above referenced Phase III clinical trials. Because of the 
potential for class effects, it is important to consider these 
additional risks when prescribing golimumab to patients. 
There are reports of new onset and exacerbation of the demy-
elinating disorders, including multiple sclerosis, in patients 
while taking TNF antagonists.21,22
Reactivation of hepatitis B virus has occurred in chronic 
carriers taking TNF antagonists and was even fatal in some 
cases, although most of these patients were also taking other 
immunosuppressive drugs.7 Chronic hepatitis C infection is 
not a contraindication to the use of TNF antagonists, but these 
patients should be closely monitored during treatment.23
There are also reports of other hematologic cytopenias 
in patients receiving other TNF antagonists, though often 
in combination with drugs that can suppress bone marrow 
function. The use of TNF antagonists may also exacerbate 
psoriasis in patients or cause new onset psoriasis.
Interactions
The manufacturer also recommends that golimumab not be 
prescribed if the patient is taking abatacept or anakinra, due to 
the increased risk of serious infections with concurrent use.7
Use of golimumab in practice
This new biologic therapy provides physicians with another 
option in the treatment of these often debilitating diseases 
and may offer certain advantages over other biologic thera-
pies. Smolen et al showed that golimumab was effective at 
improving the signs and symptoms of active rheumatoid 
arthritis in patients who had previously discontinued other 
TNF antagonists mainly for lack of effectiveness, intolerance, 
or inaccessibility. The authors suggest that golimumab is a 
possible alternative therapy when other TNF antagonists are 
not tolerated.15
Another advantage of golimumab over other TNF antago-
nists is that its dosing schedule may offer more convenience 
to the patient. It is dosed once monthly as a subcutaneous 
  injection that can be self-administered at home.7 This   schedule 
is   compared to that of other TNF blockers, including intravenous 
infusions of infliximab every 4 to 8 weeks, weekly subcutaneous 
dosing of etanercept, and every other week subcutaneous dosing 
of adalimumab for treatment of the same indications.24–26
Conclusion
Golimumab, one of the newest TNF antagonists to reach the 
market, is an appealing treatment option for patients with 
moderate to severe psoriatic arthritis. Its once monthly home 
dosing may be attractive to some patients. Golimumab may 
also be an effective alternative when patients fail treatment 
with other TNF antagonists.
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